… genetic eye disease, QR-504a for Fuchs endothelial corneal dystrophy.” Business Operations and Program Updates … protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. QR-421a is intended … with advanced FECD. Currently there are no treatment options available to stop or slow down FECD and disease …
… Fuchs Focus study of QR-504a for Fuchs Endothelial Corneal Dystrophy (FECD) is currently open for enrollment. This study … protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. QR-421a is intended … with advanced FECD. Currently there are no treatment options available to stop or slow down FECD and disease …
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting
… access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA) for sepofarsen. The PRIME … that are for indications that currently have no treatment options. To be eligible and accepted for PRIME, a medicine … PRIME, the EMA offers additional support to medicine developers including early interaction and dialogue. The …
… received orphan drug designation (ODD) from the FDA and European Medicines Agency (EMA). QR-411 targets the … QR-010 is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… (0.72) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… (0.70) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… (0.48) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… (0.25) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …